BCRX Q1 2024 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$93M+34.9% YoY

Gross Profit

$91M98.6% margin

Operating Income

-$14M-15.6% margin

Net Income

-$35M-38.1% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-0.7%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$54M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$468M

Total Liabilities

$944M

Stockholders' Equity

-$476M

Cash & Equivalents

$84M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$93M	$69M	+34.9%
Gross Profit	$91M	$68M	+34.9%
Operating Income	-$14M	-$28M	+49.0%
Net Income	-$35M	-$53M	+33.7%

Revenue Segments

Product

$89M96%

Collaborative and Other Research and Development

$3M4%